18 and older, any sex, with Recurrent Head and Neck Cancer. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Disease-free Survival at 2 YearsPrimary· 24 months
Disease-free survival measured at 2 years for all recruited participants - data retrieved from medical records retrospectively
Measured as 2 years post TORS procedure
Group
Value
95% CI
Patients With HNC Recurrence Treated With TORS
111
Overall Survival at 2 YearsSecondary· 24 months
Overall survival at 2 years - number of living participants at end of 2 year follow up - data retrieved from medical records retrospectively
Measured as 2 years post TORS procedure
Group
Value
95% CI
Patients With Head & Neck Cancer Recurrence Treated With Transoral Robotic Surgery
192
Rate of Gastrostomy Use at 1 YearSecondary· 12 months
Rate of gastrostomy use at 1 year - number of participants having a gastrostomy post surgery
Group
Value
95% CI
Patients With Head & Neck Cancer Recurrence Treated With Transoral Robotic Surgery
109
Rate of Tracheostomy Use at 1 YearSecondary· 12 months
Rate of tracheostomy use at 1 year
Group
Value
95% CI
Patients With Head & Neck Cancer Recurrence Treated With Transoral Robotic Surgery
105
Disease-specific Survival at 2 YearsPrimary· 24 months
Disease-specific survival measured at 2 years for all recruited participants - data retrieved from medical records retrospectively
Measured as 2 years post TORS procedure
Group
Value
95% CI
Patients With HNC Recurrence Treated With TORS
219
Sponsor's own description
transoral Robotic surgery for rECurrent tumours of the Upper aerodigestive Tract
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
Other recruiting trials for Recurrent Head and Neck Cancer
Currently open trials in the same condition.
NCT06869473 — Cetuximab Plus Platinum and Taxane-based Chemotherapy, Followed by Avelumab and Cetuximab, as First-line Treatment for R
· Phase 2
· recruiting
NCT06239220 — PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC
· Phase 2
· recruiting
NCT05980000 — Ramucirumab and Pembrolizumab vs Pembrolizumab Monotherapy in PD-L1 Positive Head and Neck Squamous-Cell Carcinoma
· Phase 2
· active not recruiting
Other Royal Marsden NHS Foundation Trust trials
Trials by the same sponsor.
NCT07407686 — Improving Engagement From Underserved Communities With Prostate Cancer Genetics Services
· not yet recruiting
NCT07243834 — Assessing a Digital Exercise Intervention for Health Outcomes and Engagement in Regular Exercise
· NA
· recruiting
NCT06605833 — CARDiac Toxicity Following ImmunOtherapy Treatment for Melanoma
· enrolling by invitation
NCT07008742 — Feasibility Study of Tissue and Blood Collection in Oncogene-addicted and Neoadjuvantly Treated Non Small Cell Lung Canc
· recruiting
NCT06560905 — Preoperative Planning With PSMA-PET in Melanoma Surgery Trial
· Phase 2
· recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Royal Marsden NHS Foundation Trust
Last refreshed: 9 January 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04673929.